Opioid receptor expressing neurons of the central amygdala gate behavioral effects of ketamine in mice.
Matthew B Pomrenze, Sam Vaillancourt, Pierre Llorach, Daniel Ryskamp Rijsketic, Austen B Casey, Nicholas Gregory, Juliana S Salgado, Robert C Malenka, Boris D Heifets
bioRxiv : the preprint server for biology March 6, 2024 preprint DOI: 10.1101/2024.03.03.583196
Summary
Ketamine's remarkable effects on mood and behavior depend on specific neurons in a brain region called the central amygdala. New research reveals that these neurons, which contain opioid receptors, act as gatekeepers for ketamine's impact on movement and activity. When these neurons are blocked, ketamine's effects change dramatically, suggesting they play a crucial role in how this promising medication works in the brain.
Abstract
Ketamine has anesthetic, analgesic, and antidepressant properties which may involve multiple neuromodulatory systems. In humans, the opioid receptor (OR) antagonist naltrexone blocks the antidepressant effect of ketamine. It is unclear whether naltrexone blocks a direct effect of ketamine at ORs, or whether normal functioning of the OR system is required to realize the full antidepressant effects of treatment. In mice, the effect of ketamine on locomotion, but not analgesia or the forced swim test, was sensitive to naltrexone and was therefore used as a behavioral readout to localize the effect of naltrexone in the brain. We performed whole-brain imaging of cFos expression in ketamine-treated mice, pretreated with naltrexone or vehicle, and identified the central amygdala (CeA) as the area with greatest difference in cFos intensity. CeA neurons expressing both μOR (MOR) and PKCμ were strongly activated by naltrexone but not ketamine, and selectively interrupting MOR function in the CeA either pharmacologically or genetically blocked the locomotor effects of ketamine. These data suggest that MORs expressed in CeA neurons gate behavioral effects of ketamine but are not direct targets of ketamine.